Clinical and Immunological Outcomes of Rituximab Therapy in Pemphigus: A Prospective Observational Study

Rituximab therapy demonstrates robust clinical and immunological efficacy in pemphigus, with substantial reductions in Dsg1 and Dsg3 antibody levels and high remission rates. Its use, particularly with the low RA protocol, offers a safer and more effective alternative to conventional immunosuppressive regimens. Patients on DCP therapy had slower antibody decline and greater treatment toxicity compared to rituximab, reaffirming rituximab's superiority.